Further research into the genetic and epigenetic regulation of Nrf2 in HCC could unveil new therapeutic targets within the Nrf2 signaling pathway and help in the development of more effective, personalized treatment strategies. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.